U.S. Software Stock News

After Herbalife's sharp share price moves, you might be wondering whether the current price offers value or if you are turning up late to the story. The stock recently closed at US$16.64, with a 1.9% decline over the last 7 days, a 24.8% gain over 30 days, a 29.8% gain year to date, and a 158.0% gain over the past year, set against longer term 3 year and 5 year returns of 3.4% decline and 67.3% decline respectively. Recent company news has focused on Herbalife's ongoing business performance...

SEALSQ Corp and WISeKey’s subsidiary recently signed a non-binding Memorandum of Understanding with the Government of Gujarat and Kaynes SemiCon to collaborate on establishing India’s first secure semiconductor design, test, and personalization center focused on post-quantum cryptography at Sanand, targeting capacity of up to 300 million secure chips annually. This planned joint venture, SEALKAYNESQ Ltd, is intended to support India’s onshore, quantum‑resistant semiconductor ecosystem for...

DigitalBridge Group (NYSE:DBRG) has agreed to be acquired by SoftBank for a cash consideration. The deal has triggered third party investigations into whether shareholders are receiving adequate compensation. Questions have also been raised about disclosures around the transaction and the absence of competing bids. DigitalBridge Group focuses on digital infrastructure assets, an area that sits at the intersection of data centers, networking and communications. The decision by SoftBank to...

If you are wondering whether FTAI Aviation's current share price lines up with its fundamentals, you are not alone. Many investors are asking the same question right now. The stock last closed at US$292.10, with returns of 6.7% over 7 days, 67.7% over 30 days, 38.9% year to date and 224.2% over 1 year, with the 3 year and 5 year returns both very large. Recent coverage around FTAI Aviation has focused on how its business model fits into broader themes in the aviation and leasing industry, as...

Revolution Medicines (NasdaqGS:RVMD) has attracted reported takeover interest from Merck, drawing fresh attention to the company and its pipeline. The interest surfaces as Revolution Medicines insiders, including General Counsel Jeff Cislini, have recently sold shares. Investors are weighing potential M&A activity alongside insider transactions and a sharply higher share price. Revolution Medicines enters this phase with strong recent share price moves, with the stock at $117.63 and up...

If you are wondering whether Dycom Industries is still good value after a strong run, this breakdown will help you see how the current price stacks up against different valuation yardsticks. The stock recently closed at US$368.21, with a 7 day return of a 0.6% decline, a 30 day return of 5.9%, and a 1 year return of 90.9%. The 3 year return is very large and the 5 year return is also very large. Recent news around Dycom Industries has focused on its role as a key contractor in U.S...

In recent weeks, Progyny received a series of analyst upgrades after meetings with management highlighted strong demand for its fertility benefits platform, improved earnings visibility, and nearly complete client retention heading into 2026. Analysts also emphasized Progyny’s breadth of over 600 employer clients and the absence of any single customer contributing more than 5% of revenue, underlining the resilience of its business model. Next, we’ll examine how this combination of...

Institutional investor commentaries highlight shifting sentiment on Doximity (NYSE:DOCS) following its latest quarterly results and outlook. The stock has faced pressure after cautious company guidance and recent healthcare policy changes. Hedge fund ownership has modestly increased, pointing to continued institutional interest despite recent share price moves. Doximity continues to focus on physician engagement, telehealth, and workflow tools as it responds to a rapidly changing digital...

What Recent Returns Say About Avient’s Momentum Avient (AVNT) has drawn attention after a one-month return of about 17.7% and a past three-month gain near 14.5%, against a one-year total return decline of roughly 9.6%. See our latest analysis for Avient. At a share price of $37.40, Avient’s recent 30 day share price return of 17.7% and 90 day gain of 14.5% contrast with a 1 year total shareholder return decline of 9.6%. This suggests near term momentum against a softer longer term picture. If...

If you are wondering whether Pursuit Attractions and Hospitality is offering fair value at its recent price, this article walks through the numbers in a straightforward way so you can judge for yourself. The stock recently closed at US$35.25, with returns of 5.3% over the last 7 days, 2.9% over 30 days, 5.5% year to date, 22.8% over 3 years and a 9.1% decline over 1 year, which gives a mixed picture of recent and longer term performance. Outside of regular trading updates, investors have...

If you are wondering whether STAAR Surgical's share price reflects its true value today, it helps to step back and look at how the market has been treating the stock recently. Over the last week, the share price return was 8.7% lower. The 30 day, year to date and 1 year returns were 18.0%, 18.9% and 21.7% lower respectively, and the 3 year and 5 year returns were 73.4% and 81.3% lower. This gives important context before judging any potential upside or downside. Recent coverage around STAAR...

Elanco Animal Health recently attracted a wave of upbeat analyst opinions and highlighted fresh regulatory milestones, including USDA approval for Befrena and conditional FDA approval for Credelio Quattro, while also scheduling its fourth-quarter and full-year 2025 results call for February 24, 2026. What stands out is how deeper access to corporate veterinary accounts and acceptance of price increases on core products are reshaping perceptions of Elanco’s competitive position. Next, we’ll...

CSX (NasdaqGS:CSX) is cutting 166 management roles and furloughing nearly 200 conductors as part of a broad operational restructuring. The company is responding to persistent freight market challenges that have affected its latest quarterly results. New CEO Steve Angel is prioritizing productivity efforts, technology spending, and streamlined operations to manage costs. CSX operates one of the major freight rail networks in the US, serving industrial, agricultural, and consumer end markets...

If you are asking whether NCR Atleos at US$37.63 is a bargain, fully priced, or something in between, this article is going to walk you through the key signals that matter for valuation. The stock has moved around recently, with a 5.8% decline over the last 7 days, a 3.5% decline over the last 30 days, and returns of 1.1% year to date and 15.7% over the last year. Recent coverage has focused on NCR Atleos as a stand alone ATM and financial technology infrastructure business following its...

Riverwater Partners Sustainable Value Strategy has initiated a new position in Adeia Inc. (NasdaqGS:ADEA). The position reflects fresh institutional interest in Adeia's intellectual property business across media and semiconductor markets. Adeia focuses on licensing intellectual property that underpins media content distribution and semiconductor design, areas that remain central to how video is delivered and how chips are structured and manufactured. As streaming, connected devices and...

Omnicell, ticker NasdaqGS:OMCL, has expanded its digital healthcare focus with new medication management solutions. The company has launched its XT Amplify program, aimed at supporting hospitals and health systems with medication management. These moves highlight Omnicell's efforts to align its portfolio with outcome focused digital healthcare trends. At a share price of $50.3, Omnicell is coming off a mixed return profile, with the stock up 8.4% over the past 30 days and 11.4% year to...

Arbe Robotics (ARBE) is attracting fresh attention after a sharp move in both its shares and options, with recent trading sessions showing concentrated call option activity and heavier volumes than the average month. See our latest analysis for Arbe Robotics. The latest options activity comes after a volatile stretch where the 7 day share price return of 49.12% and 30 day share price return of 65.05% contrast with a 1 year total shareholder return loss of 43.14%. This suggests short term...

Monster Beverage recently attracted attention as analysts highlighted its upcoming fiscal Q4 2025 earnings announcement, projected profit growth, and continued international momentum for its energy drink portfolio, including the expanding Zero Sugar line. Investor focus has also been reinforced by Monster’s brand-first approach, strong cash generation, and new high-profile marketing partnerships in Europe, such as its deal with F1 driver Lando Norris. Next, we’ll examine how expectations...

If you are wondering whether Live Nation Entertainment is priced attractively today, it helps to step back from the headlines and look closely at what the numbers are saying about the stock. The shares recently closed at US$146.97, with returns of 1.8% over the past week, 0.8% over the last month, 1.1% year to date, 4.4% over 1 year, 82.9% over 3 years and 121.2% over 5 years. These figures may shape how the market currently views its potential and risks. Recent news coverage around Live...

UFC has signed a multi year exclusive media rights agreement with FPT Play to broadcast UFC events in Vietnam. The deal gives FPT Play exclusive rights to distribute UFC content to viewers across Vietnam. For TKO Group Holdings (NYSE:TKO), which owns UFC, this agreement adds another piece to its international media footprint. UFC already has a global fan base, and Vietnam is a market with growing interest in combat sports and digital streaming. Partnering with an exclusive local distributor...

If you are wondering whether McKesson at around US$820 a share is still reasonably priced or starting to look expensive, you are in the right place. The stock has eased back recently, with a 2.4% decline over the last week and a 0.8% decline over the last month, although the 1 year return sits at 39.2% and the 3 year return at 119.5%. Recent coverage has focused on McKesson as one of the large distributors at the heart of the U.S. healthcare supply chain. This keeps it in the spotlight...

If you are wondering whether Moody's current share price still makes sense after a strong multi year run, this article will walk through what that price might imply about the company. Moody's closed at US$524.04, with a 2.8% decline over the last 7 days, a 1.3% gain over 30 days, a 5.0% gain year to date, a 7.8% gain over 1 year, a 68.1% gain over 3 years and a 105.2% gain over 5 years. Recent moves in the stock sit against an ongoing demand backdrop for credit ratings and analytics, as...

If you are wondering whether Interparfums at around US$98.76 is attractively priced or asking too much for its brand power, you are in the right place. The stock has recently shown sharp moves, with returns of 9.8% over 7 days and 15.8% over 30 days. It also carries a 27.8% decline over 1 year and a 6.1% decline over 3 years, alongside a 77.3% gain over 5 years. These mixed returns come against a backdrop of ongoing attention on branded fragrance and beauty companies, where investors have...

If you are wondering whether Assurant at around US$233 per share still offers value, you are not alone. The stock’s current price invites a closer look at what you are actually paying for. The share price closed at US$233.39, with returns of a 0.3% decline over 7 days, a 3.5% decline over 30 days and a 1.8% decline year to date, while the 1 year and 3 year returns stand at 12.4% and 88.5% respectively, and the 5 year return is 87.9%. Recent price moves sit against a backdrop of ongoing...